cyproheptadine hydrochloride - Profile
✉ Email this page to a colleague
What are the generic drug sources for cyproheptadine hydrochloride and what is the scope of patent protection?
Cyproheptadine hydrochloride
is the generic ingredient in two branded drugs marketed by Actavis Mid Atlantic, Chartwell Molecular, Halsey, Morton Grove, Naska, Patrin, Pharm Assoc, Quagen, Rising, St John Pharm, Tris Pharma Inc, Merck, Am Therap, Appco, Ascot, Chartwell Rx, Duramed Pharms Barr, Heritage Pharma, Ingenus Pharms Llc, Kenton, Kv Pharm, Md Pharm, Mountain, Mylan, Pioneer Pharms, Pliva, Regcon Holdings, Strides Pharma Intl, Superpharm, Vitarine, Watson Labs, and Zydus Pharms, and is included in forty-one NDAs. Additional information is available in the individual branded drug profile pages.Summary for cyproheptadine hydrochloride
| US Patents: | 0 |
| Tradenames: | 2 |
| Applicants: | 32 |
| NDAs: | 41 |
US Patents and Regulatory Information for cyproheptadine hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actavis Mid Atlantic | CYPROHEPTADINE HYDROCHLORIDE | cyproheptadine hydrochloride | SYRUP;ORAL | 086833-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Chartwell Molecular | CYPROHEPTADINE HYDROCHLORIDE | cyproheptadine hydrochloride | SYRUP;ORAL | 203191-001 | Jul 13, 2017 | AA | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Halsey | CYPROHEPTADINE HYDROCHLORIDE | cyproheptadine hydrochloride | SYRUP;ORAL | 089199-001 | Jul 3, 1986 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
